New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer

BACKGROUND: Several biomarkers have emerged as potential prognostic and predictive markers for non-small-cell lung cancer (NSCLC). Successful inhibition of angiogenesis with the antivascular endothelial growth factor antibody, bevacizumab, has improved the efficacy seen with standard cytotoxic thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Niki, Maiko, Yokoi, Takashi, Kurata, Takayasu, Nomura, Shosaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546813/
https://www.ncbi.nlm.nih.gov/pubmed/28814907
http://dx.doi.org/10.2147/LCTT.S138887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546813/
https://www.ncbi.nlm.nih.gov/pubmed/28814907
http://dx.doi.org/10.2147/LCTT.S138887

Ejemplares similares